Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Oral bioavailability and disposition of [14C]omapatrilat in healthy subjects.

Malhotra BK, Iyer RA, Soucek KM, Behr D, Liao WC, Mitroka JG, Kaul S, Cohen MB, Knupp CA.

J Clin Pharmacol. 2001 Aug;41(8):833-41.

PMID:
11504270
2.

Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.

Stevens RC, Rodman JH, Yong FH, Carey V, Knupp CA, Frenkel LM.

AIDS Res Hum Retroviruses. 2000 Mar 20;16(5):415-21.

PMID:
10772527
4.

Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.

Knupp CA, Hak LJ, Coakley DF, Falk RJ, Wagner BE, Raasch RH, van der Horst CM, Kaul S, Barbhaiya RH, Dukes GE.

Clin Pharmacol Ther. 1996 Nov;60(5):535-42.

PMID:
8941026
5.
6.
7.

Didanosine (ddl) and stavudine (d4T): absence of peripheral neurotoxicity in rabbits.

Warner WA, Bregman CL, Comereski CR, Arezzo JC, Davidson TJ, Knupp CA, Kaul S, Durham SK, Wasserman AJ, Frantz JD.

Food Chem Toxicol. 1995 Dec;33(12):1047-50.

PMID:
8847000
8.

Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine.

Grasela TH, Walawander CA, Beltangady M, Knupp CA, Martin RR, Dunkle LM, Barbhaiya RH, Pittman KA, Dolin R, Valentine FT, et al.

J Infect Dis. 1994 Jun;169(6):1250-5.

PMID:
8195601
9.

Pharmacokinetics of cefepime in patients with the sepsis syndrome.

Kieft H, Hoepelman AI, Knupp CA, van Dijk A, Branger JM, Struyvenberg A, Verhoef J.

J Antimicrob Chemother. 1993 Nov;32 Suppl B:117-22.

PMID:
8150754
10.
11.

Cefepime pharmacokinetics in cystic fibrosis.

Hamelin BA, Moore N, Knupp CA, Ruel M, Vallée F, LeBel M.

Pharmacotherapy. 1993 Sep-Oct;13(5):465-70.

PMID:
8247913
12.

Biopharmaceutics of didanosine in humans and in a model for acid-labile drugs, the pentagastrin-pretreated dog.

Knupp CA, Shyu WC, Morgenthien EA, Lee JS, Barbhaiya RH.

Pharm Res. 1993 Aug;10(8):1157-64.

PMID:
8415401
13.

Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation.

Knupp CA, Milbrath R, Barbhaiya RH.

J Clin Pharmacol. 1993 Jun;33(6):568-73.

PMID:
8366182
14.

Cefepime pharmacokinetics in patients with acute cholecystitis undergoing cholecystectomy.

Okamoto MP, Gill MA, Nakahiro RK, Bedikian A, Chin A, Yellin AE, Berne TV, Knupp CA.

Clin Pharm. 1993 Feb;12(2):134-7. No abstract available.

PMID:
8453862
15.

Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex.

Beltangady M, Knupp CA, Gustafson N, Barbhaiya RH, Dolin R, Seidlin M, Cooley TP, Rozencweig M.

Clin Infect Dis. 1993 Feb;16 Suppl 1:S26-31.

PMID:
8093845
16.
17.

Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus.

Knupp CA, Graziano FM, Dixon RM, Barbhaiya RH.

Antimicrob Agents Chemother. 1992 Oct;36(10):2075-9.

18.

Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.

Barbhaiya RH, Knupp CA, Pfeffer M, Zaccardelli D, Dukes GM, Mattern W, Pittman KA, Hak LJ.

Antimicrob Agents Chemother. 1992 Jul;36(7):1387-91. Erratum in: Antimicrob Agents Chemother 1992 Nov;36(11):2576.

19.

Lack of pharmacokinetic interaction between cefepime and amikacin in humans.

Barbhaiya RH, Knupp CA, Pfeffer M, Pittman KA.

Antimicrob Agents Chemother. 1992 Jul;36(7):1382-6.

20.

Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis.

Arguedas AG, Stutman HR, Zaleska M, Knupp CA, Marks MI, Nussbaum E.

Am J Dis Child. 1992 Jul;146(7):797-802.

PMID:
1496945
21.

Effects of age and gender on pharmacokinetics of cefepime.

Barbhaiya RH, Knupp CA, Pittman KA.

Antimicrob Agents Chemother. 1992 Jun;36(6):1181-5.

22.

Tissue concentrations of cefepime in acute cholecystitis patients.

Okamoto MP, Gill MA, Nakahiro RK, Chin A, Yellin AE, Berne TV, Sclar DA, Knupp CA, Heseltine PN, Appleman MD.

Ther Drug Monit. 1992 Jun;14(3):220-5.

PMID:
1412608
23.

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.

Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, Martin RR.

Antimicrob Agents Chemother. 1992 Mar;36(3):552-7.

24.

Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex.

Pai SM, Shukla UA, Grasela TH, Knupp CA, Dolin R, Valentine FT, McLaren C, Liebman HA, Martin RR, Pittman KA, et al.

J Clin Pharmacol. 1992 Mar;32(3):242-7.

PMID:
1564128
25.

High-performance liquid chromatographic assays for the quantification of amikacin in human plasma and urine.

Papp EA, Knupp CA, Barbhaiya RH.

J Chromatogr. 1992 Feb 7;574(1):93-9.

PMID:
1629293
26.

Food-induced reduction in bioavailability of didanosine.

Shyu WC, Knupp CA, Pittman KA, Dunkle L, Barbhaiya RH.

Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):503-7.

PMID:
1934863
27.

Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

Knupp CA, Shyu WC, Dolin R, Valentine FT, McLaren C, Martin RR, Pittman KA, Barbhaiya RH.

Clin Pharmacol Ther. 1991 May;49(5):523-35.

PMID:
1903100
28.
29.

Analysis of cefepime tissue penetration into human appendix.

Okamoto MP, Chin A, Gill MA, Yellin AE, Berne TV, Heseltine PN, Appleman MD, Knupp CA, Sclar DA.

Pharmacotherapy. 1991;11(5):353-8.

PMID:
1745620
30.

Disposition of the cephalosporin cefepime in normal and renally impaired subjects.

Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Halstenson CE, Opsahl JA, Pittman KA.

Drug Metab Dispos. 1991 Jan-Feb;19(1):68-73.

PMID:
1673424
31.

Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography.

Knupp CA, Stancato FA, Papp EA, Barbhaiya RH.

J Chromatogr. 1990 Nov 30;533:282-90. No abstract available.

PMID:
2127936
32.

Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects.

Barbhaiya RH, Knupp CA, Tenney J, Martin RR, Weidler DJ, Pittman KA.

J Clin Pharmacol. 1990 Oct;30(10):900-10.

PMID:
2229450
33.

Pharmacokinetics of cefepime in subjects with renal insufficiency.

Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DR, Pittman KA.

Clin Pharmacol Ther. 1990 Sep;48(3):268-76.

PMID:
2401125
34.

Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.

Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Martin RR.

Antimicrob Agents Chemother. 1990 Jun;34(6):1118-22.

35.
36.

Isolation and characterization of 4'-hydroxy T-2 toxin, a new metabolite of the trichothecene mycotoxin T-2.

Knupp CA, Corley DG, Tempesta MS, Swanson SP.

Drug Metab Dispos. 1987 Nov-Dec;15(6):816-20.

PMID:
2893707

Supplemental Content

Loading ...
Support Center